Jazz Pharmaceuticals plc (JAZZ) financial statements and ratios from SEC XBRL: revenue $4.6B (TTM), net margin -8.3%, revenue growth 15.5% YoY, P/E 16.9. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $4.27B |
| Revenue (TTM) | $4.6B |
| Net Margin | -8.3% |
| Operating Margin (TTM) | 19.5% |
| Net Debt / EBITDA | 2.9 |
| Interest Coverage | 17.6 |
| Revenue Growth (YoY) | 15.5% |
| EPS Growth (YoY) | -126.0% |
| FCF Growth (YoY) | 423.9% |
| P/E Ratio | 16.9 |
| EV / EBITDA | 20.0 |
| Price / Book | 3.32 |
| Price / Sales | 3.46 |
| FCF Yield | 10.0% |
| Altman Z-Score | 1.77 (distress) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.6 |
JAZZ overview · JAZZ earnings · JAZZ KPIs · JAZZ documents · JAZZ ownership · JAZZ peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.